Related Experiment Video
Updated: May 29, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.2K
Multicenter Retrospective Registry Study on BCG Use in Non-Muscle Invasive Bladder Cancer in Latin America: BLATAM
Gustavo M Villoldo1, Matias Ignacio Gonzalez2, Alvaro Vidal Faune3
1Instituto Alexander Fleming, Buenos Aires, Argentina.
Summary
Latin American bladder cancer treatment shows delays in Bacillus Calmette-Guérin (BCG) therapy initiation and inconsistent maintenance, impacting patient outcomes. Standardized protocols are needed to improve care for non-muscle invasive bladder cancer (NMIBC).
Area of Science:
- Uro-oncology
- Epidemiology
- Clinical Research
Background:
- Non-muscle invasive bladder cancer (NMIBC) is a significant health concern.
- Bacillus Calmette-Guérin (BCG) is a standard immunotherapy for NMIBC.
- Latin America faces unique challenges in cancer care delivery.
Purpose of the Study:
- Analyze NMIBC epidemiological and therapeutic data in Latin America.
- Identify factors linked to suboptimal BCG response.
- Assess areas for improving regional NMIBC treatment.
Main Methods:
- Multicenter retrospective study across Latin America (2011-2021).
- Data collected via electronic Case Report Form (CRF).
- Kaplan-Meier survival analysis for relapse-free survival (RFS).
Main Results:
- 292 NMIBC patients analyzed; 74% male, mean age 70.3.
- 26.7% of patients experienced delayed BCG induction (>60 days).
- Only 45.9% adhered to maintenance schedules; significant delays observed.
Conclusions:
- Significant deviations from NMIBC treatment guidelines in Latin America.
- Delayed BCG and inconsistent maintenance impact patient outcomes.
- Need for standardized protocols and improved adherence to enhance NMIBC care.
